首页> 外国专利> METHOD FOR EMERGENCY PREVENTION AND TREATMENT OF ACUTE RADIATION SICKNESS (VERSIONS)

METHOD FOR EMERGENCY PREVENTION AND TREATMENT OF ACUTE RADIATION SICKNESS (VERSIONS)

机译:急性辐射病(版本)的紧急预防和治疗方法

摘要

FIELD: medicine.;SUBSTANCE: group of inventions refers to medicine, namely to radiation medicine, and can be used for prevention and treatment of acute radiation sickness (ARS). First version of the method involves administering a liposomal preparation containing recombinant human alpha-protein (rhAFP) in amount of 0.1–1.0 mg/ml intravenously once after irradiation in a dose of up to 10 mg/kg of body weight in terms of rhAFP or same dose according to scheme: immediately after irradiation and 1, 3, 5, 7 days after irradiation. Second version of the method involves administering a liposomal preparation containing a recombinant human granulocyte colony-stimulating factor (rhGCSF) in amount of 0.004–0.06 mg/ml intravenously once immediately after irradiation in a dose of up to 0.2 mg/kg of body weight in terms of rhGCSF or in the same dose according to the scheme: immediately after irradiation and 1, 3, 5, 7 days after irradiation. In the third version, the acute prevention and treatment of acute radiation sickness is accompanied by administering a liposomal preparation containing rhAFP in amount of 0.1–1.0 mg/ml and rhGCSF in amount of 0.004–0.06 mg/ml. This preparation is administered intravenously once immediately after irradiation in dose of 10 mg/kg of body weight in terms of rhAFP and up to 0.2 mg/kg of body weight in terms of rhGCSF or in the same doses according to the scheme: immediately after irradiation and after 1, 3, 5, 7 days after irradiation.;EFFECT: use of the inventions enables the prevention and treatment of ARS by regulating growth, development and programmed death of hematopoietic stem cells, differentiation and activation of immune cells, stimulation of proliferation and maturation of granulocyte-containing blood leukocytes, as well as repair of radiation-damaged cell membranes.;3 cl, 4 tbl, 2 ex
机译:领域:药物;发明领域:一组发明是指药物,即放射医学,可用于预防和治疗急性放射病(ARS)。该方法的第一个版本涉及在照射后一次静脉内施用0.1-1.0 mg / ml重组人α-蛋白(rhAFP)的脂质体制剂,剂量最高为rhAFP或10 mg / kg体重根据方案使用相同剂量:照射后立即照射,照射后1、3、5、7天。该方法的第二种形式涉及在照射后立即静脉内给予脂质体制剂,该脂质体制剂中含有重组人粒细胞集落刺激因子(rhGCSF)的量为0.004-0.06 mg / ml,剂量应在照射后立即静脉内给药,剂量最高为0.2 mg / kg体重根据方案,以rhGCSF或相同剂量给药:照射后立即和照射后1、3、5、7天。在第三个版本中,伴随着急性预防和治疗急性放射病,需要使用脂质体制剂,其中含有0.1–1.0 mg / ml的rhAFP和0.004–0.06 mg / ml的rhGCSF。辐射后立即以10 mg / kg体重的剂量(以rhAFP计)和0.2 mg / kg体重的rhGCSF或根据方案按相同剂量静脉注射一次该制剂:照射后立即效果:使用本发明能够通过调节造血干细胞的生长,发育和程序性死亡,免疫细胞的分化和活化,刺激增殖来预防和治疗ARS。含粒细胞的血白细胞的成熟,成熟以及辐射损伤的细胞膜的修复。; 3 cl,4 tbl,2 ex

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号